WO2017023070A1 - Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate - Google Patents

Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate Download PDF

Info

Publication number
WO2017023070A1
WO2017023070A1 PCT/KR2016/008461 KR2016008461W WO2017023070A1 WO 2017023070 A1 WO2017023070 A1 WO 2017023070A1 KR 2016008461 W KR2016008461 W KR 2016008461W WO 2017023070 A1 WO2017023070 A1 WO 2017023070A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatigue recovery
extracellular polysaccharide
weight
mycelium culture
laccerata
Prior art date
Application number
PCT/KR2016/008461
Other languages
French (fr)
Korean (ko)
Inventor
김윤수
윤성균
신은지
Original Assignee
(주)퓨젠바이오농업회사법인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)퓨젠바이오농업회사법인 filed Critical (주)퓨젠바이오농업회사법인
Publication of WO2017023070A1 publication Critical patent/WO2017023070A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor

Definitions

  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the dry powder of the mycelium culture medium, or the extract of the mycelium culture solution It relates to a composition for promoting fatigue recovery containing as an active ingredient.
  • Fatigue is a condition in which work efficiency decreases when working, a state of constant disruption, or a condition in which the cerebral cortex is restrained. 'Can be defined.
  • fatigue or stress is a condition in which the mental and physical functions are not smoothly performed, and the fatigue is a state in which the ability to perform muscle contraction activity, that is, exercise performance ability is insufficient.
  • the reduced state (Gibson H, et al, Sports Med . 1985. 2 (2): 120-32), in contrast to physical fatigue, stresses can be interpreted as an imbalance of physical rhythm due to mental overload. Can be. Therefore, fatigue in the broad sense is a concept that includes both fatigue and stress, and can be said to be a reduction in the ability to perform physical or mental activities.
  • fatigue is a state in which work efficiency decreases mainly due to physical fatigue, and stress is mental. It refers to a state where confusion of homeostasis occurs due to fatigue (establishment of functional evaluation system related to fatigue recovery of KFDA's health functional food, research report)
  • Ceriporia laccerata is a type of white fungus, and is known to perform co-metabolism called lignin decomposition in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in an ecosystem.
  • Ceriporia laccerata Although only the use of Ceriporia laccerata culture extract in Korean Patent No. 10-1031605, filed by the present inventors, is known so far. Increasing fatigue recovery with Ceriporia laccerata has not been reported.
  • the present inventors completed the present invention by confirming that the extracellular polysaccharide isolated from Seriphoria laccerata, the mycelium culture solution of Seriphoria laccerata, dried powder or extract thereof exhibits an effect of promoting fatigue recovery. It was.
  • An object of the present invention is to provide a composition for promoting fatigue recovery and a health functional food for promoting fatigue recovery, comprising an active ingredient produced by Seriphoria laccerata.
  • Another object of the present invention is to provide a method for recovering fatigue by administering an active ingredient produced by Ceriporia laccerata, and an active ingredient produced by Ceriporia laccerata for use in the manufacture of a medicament for fatigue recovery. It is to provide a use.
  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the seriporia lacsera It provides a dry powder of another mycelium culture solution, or an extract of the mycelium culture solution of the seriporia laccerata as an active ingredient, a composition for promoting fatigue recovery and health functional food.
  • the present invention provides a method for the fatigue recovery of administering the active ingredient produced by Ceriporia laccerata, and the active ingredient produced by Ceriporia laccerata for use in the manufacture of a medicament for fatigue recovery. Provides use.
  • Composition and health functional food containing the active ingredient produced by Ceriporia lacerata ( Ceriporia lacerata ) according to the present invention as an active ingredient has excellent fatigue recovery effect.
  • FIG. 1 is a schematic diagram of a Matsumoto swimming pool using a forced swimming device of Example 2.
  • FIG. 1 is a schematic diagram of a Matsumoto swimming pool using a forced swimming device of Example 2.
  • Figure 2 is a graph showing the forced swimming time of ICR mice administered with various concentrations of the extracellular polysaccharide produced by Seriphoria lacserata.
  • Figure 3 is a graph showing the LDH concentration in serum after forced swimming of ICR mice administered with various concentrations of the extracellular polysaccharide produced by Seriphoria lacserata.
  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata containing the extracellular polysaccharide, dry powder of the mycelium culture medium or extract of the mycelium culture solution It provides a composition for promoting fatigue recovery, containing as an active ingredient.
  • extracellular polysaccharide is a part of the cell wall of a microorganism such as a fungus, and the polysaccharide is secreted to the outside of the cell to form a capillary around it or secreted into the periphery or medium as a slime. Means.
  • the extracellular polysaccharide is secreted by the microorganism to protect itself from the external environment such as antibodies, toxic substances, protozoa and bacteriophage.
  • the extracellular polysaccharide is 40 to 60% by weight of sugar and 30 to 40% by weight of protein, 40 to 50% by weight of sugar and 32 to 38% by weight of protein, or 43 to 47% by weight of sugar and 33 to 36% by weight. % Protein, and more specifically about 45% sugar and about 34% protein.
  • the sugar may contain mannose, galactose and glucose.
  • the extracellular polysaccharide may have a molecular weight of 100 ⁇ 150 kDa, 110 ⁇ 140 kDa or 115 ⁇ 125 kDa, more specifically may have a molecular weight of about 120 kDa.
  • the extracellular polysaccharide comprises the steps of: (a) preparing a mycelium culture medium of the seriporia laccerata by liquid culture of the seriporia laccerata mycelium; (b) drying the powdered mycelium culture medium of the seriporia laccerata; And (c) extracting the dry powder of the mycelium culture medium of Seriphoria laccerata with a solvent, filtering the same, and concentrating under reduced pressure.
  • the medium for the liquid culture of the seriporia laccerata mycelium in the step (a) is sugar, glucose, starch, hydrate, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and may include water, the hydrogen ion concentration may be pH 4.5 ⁇ 6.0.
  • the medium 0.2 to 3% by weight of sugar, 0.2 to 3% by weight of glucose, 0.2 to 4% by weight, 0.1 to 0.5% by weight of water, 0.1 to 0.5% by weight of wheat flour, 0.2 to 3 weight of soy flour %, 0.05% to 0.1% by weight of magnesium sulfate (MgSO 4 ), 0.05% to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05% to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) and the balance of water Can be.
  • MgSO 4 magnesium sulfate
  • KH 2 PO 4 potassium monophosphate
  • K 2 HPO 4 potassium diphosphate
  • the liquid culture in the step (a) is carried out under a blue LED light source, it can be carried out by maintaining the concentration of carbon dioxide at 1,000 ⁇ 2,000 ppm.
  • the liquid culture for example, at 20 ⁇ 28 °C, hydrogen ion concentration (pH) 4.5 ⁇ 6.0, the light source maintains a blue LED, the illuminance is 0.1 ⁇ 0.8 LUX and air is injected at 0.5 ⁇ 2.0 kgf / cm2 and carbon dioxide
  • the concentration of may be performed for 8 to 13 days while maintaining at 1,000 to 2,000 ppm. Specifically, it may be performed for 5 to 15 days at the conditions of 20 ⁇ 25 °C, pH 4.5 ⁇ 6.0, 0.5 ⁇ 2.0 kgf / cm2, carbon dioxide concentration of 1,000 ⁇ 2,000 ppm.
  • the content of the extracellular polysaccharide produced is high.
  • step (a) As the parent strain in step (a), one excellent strain stored at 1 to 5 ° C. in PDA (Potato dextrose agar) medium was used in a shaker incubator using PDB (Potato dextrose broth) medium in an Erlenmeyer flask. Maintain a constant temperature of 25 °C can be used after 7 to 9 days incubation process.
  • the culture solution or the obtained mycelium can be used as the inoculum.
  • the amount of mycelium to be added to the inoculum may be about 0.5% (w / v) based on the amount of the solution to be cultured.
  • the amount of extracellular polysaccharides does not increase as the amount of mycelia (% / 100 ml, w / v) increases, so the medium composition has the highest content of extracellular polysaccharides, not the best nutritional ratio and environmental conditions for the growth of mycelia. It is preferable to apply the selective culture conditions to form.
  • the culture solution can be separated and purified into a mycelium and an aqueous solution.
  • the solution from which the mycelium is removed by centrifugation may be repeatedly purified using a multi-sheet filter press and a vibration centrifugal separator (PALLSEP), and then irradiated with ultraviolet (UV) light for 1 minute.
  • the culture solution may be stored after sealing to remove oxygen, which may bring a change in the content of the active ingredient due to the growth of the mycelia when the mycelia exist in the culture solution.
  • step (b) the mycelia culture solution prepared in step (a) may be dried and powdered.
  • the drying may be performed for 48 to 96 hours at a temperature of 40 °C or less, more specifically 30 °C or less to prevent the disappearance of the active material.
  • the drying of step (b) is preferable to use a vacuum freeze dryer rather than a vacuum dryer that sets the evaporation temperature relatively high because the change in the effective substance content is minimized.
  • step (c) after extracting the dry powder of the mycelia culture solution obtained in step (b) with a solvent, the extracellular polysaccharide which is the active ingredient of the composition according to the present invention is separated.
  • distilled water 100 ml of distilled water is added to the dry powder of 3 to 10 g of the mycelium culture medium, and then suspended well, followed by centrifugation at 5,000 to 10,000 rpm for 10 to 30 minutes to obtain a supernatant.
  • An extraction solvent corresponding to a pear may be added and placed in a refrigerator at 1 to 5 ° C. for 10 to 15 hours. After only centrifuging the supernatant again at 5,000 to 10,000 rpm for 10 to 30 minutes in the stationary material, the precipitate may be recovered to prepare a crude extracellular polysaccharide.
  • the crude extracellular polysaccharide can be vacuum-dried at 30 ° C. or lower to obtain extracellular polysaccharide.
  • the extraction solvent may be a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, acetone, ether, chloroform and ethyl acetate or a mixed solvent thereof, and more specifically, water, methanol, ethanol, butanol It may be a solvent selected from the group consisting of acetone and ethyl acetate or a mixed solvent thereof, and more specifically, may be water or 50 to 80% (v / v) ethanol aqueous solution.
  • the composition for promoting fatigue recovery of the present invention not only provides excellent fatigue recovery enhancing effect but also has little toxicity and side effects due to the drug, so that it can be used with confidence even during long-term use.
  • the fatigue recovery promoting effect means the action of preventing or inhibiting the symptoms resulting from the increase in lactate dehydrogenase (LDH).
  • LDH lactate dehydrogenase
  • the composition for promoting fatigue recovery of the present invention showed a fatigue recovery enhancing effect by reducing the LDH concentration of the administration group.
  • composition for promoting fatigue recovery according to the present invention may further include appropriate carriers, excipients and diluents commonly used.
  • the fatigue recovery enhancing composition may include 0.1 to 80% by weight, specifically, 0.1 to 50% by weight of the extracellular polysaccharides relative to the total weight of the composition.
  • the composition for promoting fatigue recovery may be appropriately included in the amount corresponding to the content of the extracellular polysaccharide, the mycelium culture medium, dry powder thereof or the extract of the mycelium culture medium of the three liporia laccerata.
  • the effective amount of the extracellular polysaccharide, the culture solution containing the same, the dry powder of the culture solution or the extract of the culture solution may be appropriately adjusted according to the method of use and purpose of the composition.
  • compositions according to the invention can each be formulated and used according to conventional methods. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
  • composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, when the formulation is a tablet, coated tablet, dragee and hard capsule, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof can be used. In addition, when the formulation is a soft capsule, polyols of vegetable oils, waxes, fats, semisolids and liquids can be used. In addition, when the formulation is in the form of a solution or syrup, water, polyols, glycerol, vegetable oils and the like can be used.
  • composition according to the present invention may further include a preservative, a stabilizer, a wetting agent, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic agent, an antioxidant, and the like in addition to the above carrier.
  • the method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally.
  • the dosage may vary depending on the patient's age, sex, weight, severity, and route of administration, but is generally 5 to 500 mg / kg body weight, specifically 100 to 250 based on the extracellular polysaccharide as an active ingredient.
  • the amount of mg / kg body weight may be administered once to three times a day.
  • the dosage does not limit the scope of the invention in any aspect.
  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the same, the dry powder of the mycelium culture solution or the extract of the mycelium culture solution active ingredient Including, to provide a functional dietary supplement for fatigue recovery.
  • the extracellular polysaccharide produced by the Seriphoria laccerata, the mycelium culture solution of the Seriporia laccerata, the dry powder of the mycelium culture solution or the extract of the mycelium culture medium are as described above.
  • the health functional food according to the present invention may be in the form of powder, granules, tablets, capsules or beverages, and may be candy, chocolate, beverages, gums, teas, vitamin complexes or dietary supplements.
  • the content of the extracellular polysaccharide according to the present invention contained in the health functional food, mycelium culture medium containing the same, the dry powder of the mycelium culture medium or the extract of the mycelium culture medium usually 0.01 to 50% by weight of the total food weight Specifically, it may be included in 0.1 to 20% by weight.
  • the health functional food is a beverage, based on 100 ml of the beverage, extracellular polysaccharide according to the present invention, mycelium culture medium containing the same, dry powder of the mycelium culture medium or extract of the mycelium culture medium, 0.02 to 10 g
  • the content may be included in an amount of 0.3 to 1 g.
  • the health functional food further comprises a food supplement acceptable with the extracellular polysaccharide of the present invention, a mycelium culture medium of the seriporia laccerata containing the same, a dry powder of the mycelium culture medium or an extract of the mycelium culture medium. Can be.
  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the dry powder of the mycelium culture medium, or the extract of the mycelium culture solution It provides a method for fatigue recovery, comprising administering to a subject in need of fatigue recovery.
  • the subject may be a mammalian animal, more specifically a human.
  • the present invention is an extracellular polysaccharide produced by Ceriporia lacerata for use in the manufacture of a medicament for fatigue recovery, mycelium culture medium of the Ceriporia laccerata comprising the extracellular polysaccharide. It provides a dry powder of the mycelium broth, or the use of the extract of the mycelium broth.
  • the extracellular polysaccharide produced by the Seriphoria laccerata, the mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide, the dry powder of the mycelium culture solution, or the extract of the mycelium culture medium is as described above.
  • the seedlings grown in subcultured oak reimbursement in Sangju, Gyeongbuk were grown by subculture and stored frozen at -80 °C.
  • the cryopreserved strain was passaged 2-3 times in PDA (Potato dextrose agar) medium (87 plastic cultures; Difco, Becton Dickinson and Company) and stored the strain (hereinafter referred to as “PDA culture strain”) in a 4 ° C. refrigerator. was used.
  • PDA culture strain PDA (Potato dextrose agar) medium (87 plastic cultures; Difco, Becton Dickinson and Company) and stored the strain (hereinafter referred to as “PDA culture strain”) in a 4 ° C. refrigerator.
  • PDA culture strain 87 plastic cultures; Difco, Becton Dickinson and Company
  • the dry powder of the mycelium culture medium of Seriphoria laccerata was prepared by lyophilizing the culture medium of the culture medium of Liporice laccerata prepared in Preparation Example 1-1 by lyophilizing at 25 ° C. for 72 hours.
  • the extract of the mycelium culture medium of Seriphoria laccerata prepared in Preparation Example 1-3 was further centrifuged at 8,000 rpm for 20 minutes, and the precipitate was recovered to obtain a crude EPS.
  • the crude EPS was vacuum-dried at 25 ° C. for 72 hours using a vacuum freeze dryer to obtain EPS produced by Ceriporia laccerata.
  • the EPS prepared in Preparation Example 1 was dissolved in 0.1 M Na 2 SO 4 /0.05 M NaN 3 [adjusting pH to 4 with glacial acetic acid] to 1% (w / v) in a solution, and then at 4,000 rpm. After centrifugation for 0.5 hour, only the supernatant was filtered with a 0.45 ⁇ m syringe filter and analyzed by GPC.
  • the refractive index was used as the detector, and the GPC column was adjusted to pH 4 with 0.1 M Na 2 SO 4 /0.05 M NaN 3 [glacial acetic acid using OHpak SB 805 HQ (Shodex, Japan). ], The flow rate of the mobile phase was flowed at a rate of 1.0 mL / min. Standard curves were prepared using Dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa, or 1200 kDa), and Knauer K-2310 (refractive index (RI) measuring instrument). Germany) to determine the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
  • the molecular weight of EPS of the present invention was found to be about 120 kDa.
  • the EPS prepared in Preparation Example 1 was second-purified and treated with proteolytic enzymes to determine sugar and protein content.
  • the super purified EPS (EPS prepared in Preparation Example 1) was dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant. Ethanol corresponding to 2-3 times the volume of the supernatant was added to the separated supernatant and placed in a 4 ° C. refrigerator for 12 hours. Thereafter, only the supernatant was again centrifuged at 8,000 rpm for 20 minutes, and the precipitate was recovered to obtain a second purified EPS.
  • the second purified EPS was dissolved in distilled water, and the proteolytic enzyme alcalase was treated at 50 ° C. for 30 minutes at a concentration of 0.5% (w / v).
  • Sugar content was measured by the phenol-sulfuric acid method. Specifically, 25 ⁇ l of 80% (w / v) phenol was added to 1 mL of the sample diluted by concentration, and then 2.5 mL of sulfuric acid was added and cooled to room temperature. The absorbance was measured at 465 nm to calculate the sugar content.
  • the protein content was measured by the BCA method (Smith PK et al., Analytical Biochemistry , 150 (1): 76-85, 1985), and bovine serum albumin was used as a standard.
  • EPS mainly contained mannose, galactose and glucose.
  • ICR mice 8-week-old ICR mice were prepared by dispersing EPS of Preparation Example 1 in drinking water and administered to experimental animals for 1 week using zonation.
  • the dose was 100 mg / kg body weight, 250 mg / kg body weight or 500 mg / kg body weight once daily.
  • red ginseng concentrate manufactured by Jeong Kwan Jang, product name: red ginseng tablet plus
  • the forced swimming device used the Matsumoto swimming pool shown in Fig. 1 and the flow rate was adjusted to 30 L / min.
  • the swimming time was significantly increased in the experimental group administered 100 mg / kg body weight or 250 mg / kg body weight of the EPS of the present invention when compared to the negative control group and the positive control group during the forced swimming on the third day of the experiment. It was. In addition, the swimming time was increased in the experimental group administered the EPS of the present invention during the forced swimming on the 7th day of the experiment.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to extracellular polysaccharides produced by Ceriporia lacerate, a mycelial culture broth of Ceriporia lacerate, containing the extracellular polysaccharides, a composition for promoting fatigue recovery containing, as an active ingredient, a dried powder of the mycelial culture broth or an extract of the mycelial culture broth, and a health functional food for promoting fatigue recovery. The composition and health functional food of the present invention have an excellent fatigue recovery effect.

Description

세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 피로회복 증진용 조성물Fatigue recovery enhancing composition containing an extracellular polysaccharide produced by Ceriporia laccerata as an active ingredient
본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는 피로회복 증진용 조성물에 관한 것이다.The present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the dry powder of the mycelium culture medium, or the extract of the mycelium culture solution It relates to a composition for promoting fatigue recovery containing as an active ingredient.
통상적으로 '피로'란 '작업을 할 때 작업능률이 저하되는 상태', '항상성의 혼란이 일어나는 상태' 또는 '대뇌피질의 제지작용이 일어나는 상태'로서 '육체적·정신적 활동을 하기 위한 능력의 감소'라고 정의할 수 있다.Fatigue is a condition in which work efficiency decreases when working, a state of constant disruption, or a condition in which the cerebral cortex is restrained. 'Can be defined.
피로(fatigue) 혹은 스트레스(stress)가 쌓였다고 표현하는 것은 심신의 기능이 원활히 이루어지지 않는 경우를 이르는 것으로서, 상기 피로는 근 수축 활동에 요구되는 힘을 충분히 발휘하지 못하는 상태, 즉 운동수행능력이 감소된 상태(Gibson H, et al, Sports Med. 1985. 2(2):120-32)라고 할 수 있으며, 육체적인 피로와는 대조적으로 스트레스는 정신적인 과부하로 인해 오는 신체리듬의 불균형으로 이해할 수 있다. 따라서 넓은 의미의 피로는 fatigue와 stress를 모두 포함하는 개념으로 육체적 또는 정신적 활동을 하기 위한 능력의 감소라고 할 수 있고, 구체적으로는 fatigue는 주로 육체적 피로로 작업능률이 저하되는 상태, 그리고 stress는 정신적 피로로 항상성의 혼란이 일어나는 상태를 말한다(식약청 건강기능식품의 피로회복 관련 기능성 평가체계 구축, 연구결과보고서).The expression of fatigue or stress is a condition in which the mental and physical functions are not smoothly performed, and the fatigue is a state in which the ability to perform muscle contraction activity, that is, exercise performance ability is insufficient. The reduced state (Gibson H, et al, Sports Med . 1985. 2 (2): 120-32), in contrast to physical fatigue, stresses can be interpreted as an imbalance of physical rhythm due to mental overload. Can be. Therefore, fatigue in the broad sense is a concept that includes both fatigue and stress, and can be said to be a reduction in the ability to perform physical or mental activities. Specifically, fatigue is a state in which work efficiency decreases mainly due to physical fatigue, and stress is mental. It refers to a state where confusion of homeostasis occurs due to fatigue (establishment of functional evaluation system related to fatigue recovery of KFDA's health functional food, research report)
또한, 피로의 축적은 자칫 만성피로를 유발하고, 소화성 궤양, 고혈압, 당뇨병 등의 많은 질병을 유발할 수 있다. 그리고 암, 뇌졸증, 심장질환은 현대인의 주요 3대 사망원인이기도 하며, 과로는 이들의 주요 원인이 되고 있는 실정이다. 최근 효율적인 피로회복을 위한 과학적인 식품 섭취에 대한 필요성이 증가하고 있다.In addition, the accumulation of fatigue often leads to chronic fatigue and can lead to many diseases such as peptic ulcer, hypertension, diabetes and the like. Cancer, stroke, and heart disease are the three major causes of death in modern people, and overwork is the main cause of their deaths. Recently, the need for scientific food intake for efficient fatigue recovery is increasing.
한편, 세리포리아 락세라타는 백색 부후균의 일종으로서, 생태계에서 셀룰로오스, 헤미 셀룰로오스, 기타 다당류 및 글리세롤 등의 탄소원을 이용하기 위하여 리그닌 분해라는 공동대사(co-metabolism)를 수행하는 것으로 알려져 있다.On the other hand, Ceriporia laccerata is a type of white fungus, and is known to perform co-metabolism called lignin decomposition in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in an ecosystem.
세리포리아 락세라타를 이용한 의학적 치료 용도와 관련하여, 본 발명자들에 의하여 출원된 대한민국 등록특허 제10-1031605호에 세리포리아 락세라타 배양액 추출물의 당뇨 치료 용도만이 지금까지 알려져 있을 뿐, 세리포리아 락세라타를 이용한 피로회복 증진 효과는 아직까지 보고된 바 없다.Regarding the medical treatment using Ceriporia laccerata, only the use of Ceriporia laccerata culture extract in Korean Patent No. 10-1031605, filed by the present inventors, is known so far. Increasing fatigue recovery with Ceriporia laccerata has not been reported.
이에, 본 발명자들은 세리포리아 락세라타로부터 분리한 세포외다당체, 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 추출물이 피로회복 증진 효과를 나타낸다는 것을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming that the extracellular polysaccharide isolated from Seriphoria laccerata, the mycelium culture solution of Seriphoria laccerata, dried powder or extract thereof exhibits an effect of promoting fatigue recovery. It was.
본 발명의 목적은 세리포리아 락세라타에 의해 생산되는 활성 성분을 함유하는 피로회복 증진용 조성물 및 피로회복 증진용 건강기능식품을 제공하는 것이다.SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for promoting fatigue recovery and a health functional food for promoting fatigue recovery, comprising an active ingredient produced by Seriphoria laccerata.
본 발명의 다른 목적은 세리포리아 락세라타에 의해 생산되는 활성 성분을 투여하는 피로회복 방법, 및 피로회복을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타에 의해 생산되는 활성 성분의 용도를 제공하는 것이다.Another object of the present invention is to provide a method for recovering fatigue by administering an active ingredient produced by Ceriporia laccerata, and an active ingredient produced by Ceriporia laccerata for use in the manufacture of a medicament for fatigue recovery. It is to provide a use.
상기 목적을 달성하기 위하여, 본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 세리포리아 락세라타의 균사체 배양액의 건조분말, 또는 상기 세리포리아 락세라타의 균사체 배양액의 추출물을 유효성분으로 함유하는, 피로회복 증진용 조성물 및 건강기능식품을 제공한다.In order to achieve the above object, the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the seriporia lacsera It provides a dry powder of another mycelium culture solution, or an extract of the mycelium culture solution of the seriporia laccerata as an active ingredient, a composition for promoting fatigue recovery and health functional food.
또한, 본 발명은 세리포리아 락세라타에 의해 생산되는 활성 성분을 투여하는 피로회복 방법, 및 피로회복을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타에 의해 생산되는 활성 성분의 용도를 제공한다.In addition, the present invention provides a method for the fatigue recovery of administering the active ingredient produced by Ceriporia laccerata, and the active ingredient produced by Ceriporia laccerata for use in the manufacture of a medicament for fatigue recovery. Provides use.
본 발명에 따른 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 활성 성분을 유효성분으로 함유하는 조성물 및 건강기능식품은 피로회복 효과가 우수하다.Composition and health functional food containing the active ingredient produced by Ceriporia lacerata ( Ceriporia lacerata ) according to the present invention as an active ingredient has excellent fatigue recovery effect.
도 1은 실시예 2의 강제수영장치를 이용한 마츠모토식 유영유수조의 모식도이다.1 is a schematic diagram of a Matsumoto swimming pool using a forced swimming device of Example 2. FIG.
도 2는 세리포리아 락세라타에 의해 생산되는 세포외다당체를 다양한 농도로 투여한 ICR 마우스의 강제수영 시간을 나타낸 그래프이다.Figure 2 is a graph showing the forced swimming time of ICR mice administered with various concentrations of the extracellular polysaccharide produced by Seriphoria lacserata.
도 3은 세리포리아 락세라타에 의해 생산되는 세포외다당체를 다양한 농도로 투여한 ICR 마우스의 강제수영 이후 혈청 내 LDH 농도를 나타낸 그래프이다.Figure 3 is a graph showing the LDH concentration in serum after forced swimming of ICR mice administered with various concentrations of the extracellular polysaccharide produced by Seriphoria lacserata.
본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는, 피로회복 증진용 조성물을 제공한다.The present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata containing the extracellular polysaccharide, dry powder of the mycelium culture medium or extract of the mycelium culture solution It provides a composition for promoting fatigue recovery, containing as an active ingredient.
본 명세서에서 사용된 용어 "세포외다당체(extracellular polysaccharide, EPS)"란, 균류 등 미생물의 세포벽의 일부로서, 다당류가 세포 외로 분비되어 그 주위에 협막을 형성하거나 점질물로서 세포주위나 배지로 분비되는 물질을 의미한다. 상기 세포외다당체는 미생물이 항체, 독성물질, 원생동물 및 박테리오파지 등의 외부환경으로부터 자신을 보호하기 위해 분비된다.As used herein, the term "extracellular polysaccharide (EPS)" is a part of the cell wall of a microorganism such as a fungus, and the polysaccharide is secreted to the outside of the cell to form a capillary around it or secreted into the periphery or medium as a slime. Means. The extracellular polysaccharide is secreted by the microorganism to protect itself from the external environment such as antibodies, toxic substances, protozoa and bacteriophage.
상기 세포외다당체는 40 ~ 60 중량%의 당 및 30 ~ 40 중량%의 단백질, 40 ~ 50 중량%의 당 및 32 ~ 38 중량%의 단백질, 또는 43 ~ 47 중량%의 당 및 33 ~ 36 중량%의 단백질을 포함할 수 있고, 보다 구체적으로는 약 45 중량%의 당 및 약 34 중량%의 단백질을 포함할 수 있다.The extracellular polysaccharide is 40 to 60% by weight of sugar and 30 to 40% by weight of protein, 40 to 50% by weight of sugar and 32 to 38% by weight of protein, or 43 to 47% by weight of sugar and 33 to 36% by weight. % Protein, and more specifically about 45% sugar and about 34% protein.
상기 당은 만노오스, 갈락토오스 및 글루코오스를 함유할 수 있다.The sugar may contain mannose, galactose and glucose.
상기 세포외다당체는 100 ~ 150 kDa, 110 ~ 140 kDa 또는 115 ~ 125 kDa의 분자량을 가질 수 있고, 보다 구체적으로는 약 120 kDa의 분자량을 가질 수 있다.The extracellular polysaccharide may have a molecular weight of 100 ~ 150 kDa, 110 ~ 140 kDa or 115 ~ 125 kDa, more specifically may have a molecular weight of about 120 kDa.
본 발명의 일구체예로서, 상기 세포외다당체는, (a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타의 균사체 배양액을 제조하는 단계; (b) 상기 세리포리아 락세라타의 균사체 배양액을 건조시켜 분말화하는 단계; 및 (c) 세리포리아 락세라타의 균사체 배양액의 건조분말을 용매로 추출한 후 이를 여과하고 감압농축하는 단계를 포함하는 제조방법에 의하여 제조될 수 있다.In one embodiment of the present invention, the extracellular polysaccharide comprises the steps of: (a) preparing a mycelium culture medium of the seriporia laccerata by liquid culture of the seriporia laccerata mycelium; (b) drying the powdered mycelium culture medium of the seriporia laccerata; And (c) extracting the dry powder of the mycelium culture medium of Seriphoria laccerata with a solvent, filtering the same, and concentrating under reduced pressure.
상기 (a) 단계에서의 세리포리아 락세라타 균사체의 액체 배양을 위한 배지는 설탕, 포도당, 전분, 수수분, 대맥분, 대두분, 황산마그네슘(MgSO4), 1인산칼륨(KH2PO4), 2인산칼륨(K2HPO4) 및 물을 포함할 수 있고, 수소이온농도가 pH 4.5 ~ 6.0인 것일 수 있다.The medium for the liquid culture of the seriporia laccerata mycelium in the step (a) is sugar, glucose, starch, hydrate, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and may include water, the hydrogen ion concentration may be pH 4.5 ~ 6.0.
구체적으로, 상기 배지는, 설탕 0.2 ~ 3 중량%, 포도당 0.2 ~ 3 중량%, 전분 0.2 ~ 4 중량%, 수수분 0.1 ~ 0.5 중량%, 대맥분 0.1 ~ 0.5 중량%, 대두분 0.2 ~ 3 중량%, 황산마그네슘(MgSO4) 0.05 ~ 0.1 중량%, 1인산칼륨(KH2PO4) 0.05 ~ 0.25 중량%, 2인산칼륨(K2HPO4) 0.05 ~ 0.25 중량% 및 잔량의 물을 포함할 수 있다.Specifically, the medium, 0.2 to 3% by weight of sugar, 0.2 to 3% by weight of glucose, 0.2 to 4% by weight, 0.1 to 0.5% by weight of water, 0.1 to 0.5% by weight of wheat flour, 0.2 to 3 weight of soy flour %, 0.05% to 0.1% by weight of magnesium sulfate (MgSO 4 ), 0.05% to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05% to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) and the balance of water Can be.
상기 (a) 단계에서의 액체 배양은 청색 LED 광원 하에서 수행되고, 이산화탄소의 농도를 1,000 ~ 2,000 ppm으로 유지하여 수행될 수 있다.The liquid culture in the step (a) is carried out under a blue LED light source, it can be carried out by maintaining the concentration of carbon dioxide at 1,000 ~ 2,000 ppm.
상기 액체 배양은 예를 들어, 20 ~ 28 ℃에서, 수소이온농도(pH) 4.5 ~ 6.0, 광원은 청색 LED, 조도는 0.1 ~ 0.8 LUX를 유지하며 공기는 0.5 ~ 2.0 kgf/㎠으로 주입하고 이산화탄소의 농도는 1,000 ~ 2,000 ppm으로 유지하면서 8 ~ 13일간 수행될 수 있다. 구체적으로, 20 ~ 25 ℃, pH 4.5 ~ 6.0, 0.5 ~ 2.0 kgf/㎠, 1,000 ~ 2,000 ppm의 이산화탄소 농도의 조건에서 5 ~ 15일간 수행될 수 있다. 상술한 바와 같은 조건으로 액체 배양할 경우, 생산되는 세포외다당체의 함량이 높으므로 바람직하다.The liquid culture, for example, at 20 ~ 28 ℃, hydrogen ion concentration (pH) 4.5 ~ 6.0, the light source maintains a blue LED, the illuminance is 0.1 ~ 0.8 LUX and air is injected at 0.5 ~ 2.0 kgf / ㎠ and carbon dioxide The concentration of may be performed for 8 to 13 days while maintaining at 1,000 to 2,000 ppm. Specifically, it may be performed for 5 to 15 days at the conditions of 20 ~ 25 ℃, pH 4.5 ~ 6.0, 0.5 ~ 2.0 kgf / ㎠, carbon dioxide concentration of 1,000 ~ 2,000 ppm. When the liquid culture under the conditions described above, the content of the extracellular polysaccharide produced is high.
상기 (a) 단계에서의 모균주로는 PDA(Potato dextrose agar) 배지 상태로 1 ~ 5 ℃에 보관중인 우량 균주 1개를, 삼각플라스크에 PDB(Potato dextrose broth) 배지를 사용하여 진탕 배양기에서 약 25 ℃의 항온을 유지하며 7 ~ 9일간 배양과정을 거친 후 사용할 수 있다. 또한, 이와 같이 모균주를 배양한 후 배양액 또는 수득한 균사체를 접종원으로 이용할 수 있다. 구체적으로, 접종원으로 투입될 균사체의 양은 배양할 용액의 양을 기준으로 0.5 %(w/v) 정도일 수 있다. 균사체량(%/100 ㎖, w/v)이 많다고 세포외다당체의 함량도 같이 높아지는 것이 아니므로 배지 조성은 균사체의 성장에 가장 양호한 영양 비율 및 환경조건이 아닌, 세포외다당체의 함량을 가장 높게 형성시키는 선택적 배양조건을 적용하는 것이 바람직하다.As the parent strain in step (a), one excellent strain stored at 1 to 5 ° C. in PDA (Potato dextrose agar) medium was used in a shaker incubator using PDB (Potato dextrose broth) medium in an Erlenmeyer flask. Maintain a constant temperature of 25 ℃ can be used after 7 to 9 days incubation process. In addition, after culturing the parent strains, the culture solution or the obtained mycelium can be used as the inoculum. Specifically, the amount of mycelium to be added to the inoculum may be about 0.5% (w / v) based on the amount of the solution to be cultured. The amount of extracellular polysaccharides does not increase as the amount of mycelia (% / 100 ml, w / v) increases, so the medium composition has the highest content of extracellular polysaccharides, not the best nutritional ratio and environmental conditions for the growth of mycelia. It is preferable to apply the selective culture conditions to form.
상기 배양액은 균사체와 수용액으로 분리 정제할 수 있다. 상기 분리 정제를 위해 원심분리기로 균사체를 제거한 용액을 다중필터프레스(Multi-Sheet Filter Press)와 진동원심막분리기(PALLSEP)로 반복하여 정제한 후 1분간 자외선(UV)을 조사할 수 있다. 또한, 배양액은 산소를 제거한 후 밀봉하여 보관할 수 있으며, 이는 배양액 속에 균사가 존재할 경우 균사의 성장으로 유효성분의 함량에 변화를 가져올 수 있다.The culture solution can be separated and purified into a mycelium and an aqueous solution. For the separation and purification, the solution from which the mycelium is removed by centrifugation may be repeatedly purified using a multi-sheet filter press and a vibration centrifugal separator (PALLSEP), and then irradiated with ultraviolet (UV) light for 1 minute. In addition, the culture solution may be stored after sealing to remove oxygen, which may bring a change in the content of the active ingredient due to the growth of the mycelia when the mycelia exist in the culture solution.
상기 (b) 단계에서는 상기 (a) 단계에서 제조된 균사체 배양액을 건조시켜 분말화할 수 있다. 상기 건조는 유효물질의 소멸을 방지하기 위해 40 ℃ 이하의 온도, 보다 구체적으로는 30 ℃ 이하의 온도에서 48 내지 96시간 동안 수행될 수 있다. 또한, (b) 단계의 건조는 증발온도를 상대적으로 높게 설정하는 진공건조기보다 진공동결건조기를 사용하는 것이 유효물질 함량 변화가 최소화되므로 바람직하다.In step (b), the mycelia culture solution prepared in step (a) may be dried and powdered. The drying may be performed for 48 to 96 hours at a temperature of 40 ℃ or less, more specifically 30 ℃ or less to prevent the disappearance of the active material. In addition, the drying of step (b) is preferable to use a vacuum freeze dryer rather than a vacuum dryer that sets the evaporation temperature relatively high because the change in the effective substance content is minimized.
상기 (c) 단계에서는 (b) 단계에서 얻은 균사체 배양액 건조분말을 용매로 추출한 후, 본 발명에 따른 조성물의 유효성분인 세포외다당체를 분리한다. In the step (c), after extracting the dry powder of the mycelia culture solution obtained in step (b) with a solvent, the extracellular polysaccharide which is the active ingredient of the composition according to the present invention is separated.
구체적으로, 균사체 배양액 건조분말 3 ~ 10 g에 증류수 100 ㎖를 첨가하여 잘 현탁한 후, 5,000 ~ 10,000 rpm으로 10 ~ 30 분 동안 원심분리하여 상등액을 수득하고, 상기 상등액에 상등액 부피의 2 ~ 3배에 해당하는 추출 용매를 첨가하고 1 ~ 5℃의 냉장고에 넣어 10 ~ 15시간 정치시킬 수 있다. 상기의 정치물에서 상등액만을 다시 5,000 ~ 10,000 rpm으로 10 ~ 30분 동안 원심분리한 후, 침전물을 회수하여 조(crude) 세포외다당체를 제조할 수 있다. 상기 조 세포외다당체를 30 ℃ 이하에서 진공동결건조하여 세포외다당체를 수득할 수 있다.Specifically, 100 ml of distilled water is added to the dry powder of 3 to 10 g of the mycelium culture medium, and then suspended well, followed by centrifugation at 5,000 to 10,000 rpm for 10 to 30 minutes to obtain a supernatant. An extraction solvent corresponding to a pear may be added and placed in a refrigerator at 1 to 5 ° C. for 10 to 15 hours. After only centrifuging the supernatant again at 5,000 to 10,000 rpm for 10 to 30 minutes in the stationary material, the precipitate may be recovered to prepare a crude extracellular polysaccharide. The crude extracellular polysaccharide can be vacuum-dried at 30 ° C. or lower to obtain extracellular polysaccharide.
상기 추출 용매는 물, 탄소수 1 내지 4의 저급 알코올, 아세톤, 에테르, 클로로포름 및 에틸아세테이트로 이루어진 군에서 선택되는 용매 또는 이들의 혼합용매일 수 있고, 보다 구체적으로는, 물, 메탄올, 에탄올, 부탄올, 아세톤 및 에틸아세테이트로 이루어진 군에서 선택되는 용매 또는 이들의 혼합용매일 수 있으며, 더욱 구체적으로는, 물 또는 50 내지 80 %(v/v)의 에탄올 수용액일 수 있다.The extraction solvent may be a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, acetone, ether, chloroform and ethyl acetate or a mixed solvent thereof, and more specifically, water, methanol, ethanol, butanol It may be a solvent selected from the group consisting of acetone and ethyl acetate or a mixed solvent thereof, and more specifically, may be water or 50 to 80% (v / v) ethanol aqueous solution.
본 발명의 피로회복 증진용 조성물은 우수한 피로회복 증진 효과를 제공할 뿐만 아니라 약물에 의한 독성 및 부작용도 거의 없어 장기간 복용시에도 안심하고 사용할 수 있다. 상기 피로회복 증진 효과는 락트산 탈수소효소(lactate dehydrogenase; LDH)의 증가에서 비롯되는 증상이 예방 또는 억제되는 작용을 의미한다. 본 발명의 일구현예에 따르면, 본 발명의 피로회복 증진용 조성물은 투여군의 LDH 농도를 감소시켜 피로회복 증진 효과를 나타냈다.The composition for promoting fatigue recovery of the present invention not only provides excellent fatigue recovery enhancing effect but also has little toxicity and side effects due to the drug, so that it can be used with confidence even during long-term use. The fatigue recovery promoting effect means the action of preventing or inhibiting the symptoms resulting from the increase in lactate dehydrogenase (LDH). According to one embodiment of the present invention, the composition for promoting fatigue recovery of the present invention showed a fatigue recovery enhancing effect by reducing the LDH concentration of the administration group.
본 발명에 따른 피로회복 증진용 조성물은 통상적으로 사용되는 적절한 담체, 부형제 및 희석제가 더 포함될 수 있다.The composition for promoting fatigue recovery according to the present invention may further include appropriate carriers, excipients and diluents commonly used.
상기 피로회복 증진용 조성물은 조성물 총 중량 대비 0.1 내지 80 중량%, 구체적으로, 0.1 내지 50 중량%의 세포외다당체를 포함할 수 있다. 또한, 상기 피로회복 증진용 조성물은 세리포리아 락세라타의 균사체 배양액, 이의 건조분말 또는 상기 균사체 배양액의 추출물은 상기 세포외다당체의 함량에 해당하는 양으로 적절히 포함될 수 있다. 그러나, 세포외다당체, 이를 포함하는 배양액, 상기 배양액의 건조분말 또는 상기 배양액의 추출물의 유효 함량은 상기 조성물의 사용방법 및 목적에 따라 적절히 조절될 수 있다.The fatigue recovery enhancing composition may include 0.1 to 80% by weight, specifically, 0.1 to 50% by weight of the extracellular polysaccharides relative to the total weight of the composition. In addition, the composition for promoting fatigue recovery may be appropriately included in the amount corresponding to the content of the extracellular polysaccharide, the mycelium culture medium, dry powder thereof or the extract of the mycelium culture medium of the three liporia laccerata. However, the effective amount of the extracellular polysaccharide, the culture solution containing the same, the dry powder of the culture solution or the extract of the culture solution may be appropriately adjusted according to the method of use and purpose of the composition.
본 발명에 따른 조성물은 각각 통상의 방법에 따라 제형화하여 사용될 수 있다. 적합한 제형으로는 정제, 환제, 산제, 과립제, 당의정, 경질 또는 연질의 캡슐제, 용액제, 현탁제 또는 유화액제, 주사제, 좌제 등이 있으나, 이에 한정되는 것은 아니다.The compositions according to the invention can each be formulated and used according to conventional methods. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
본 발명에 따른 조성물은 약학적으로 불활성인 유기 또는 무기 담체를 이용하여 적합한 제형으로 제조할 수 있다. 즉, 제형이 정제, 코팅된 정제, 당의정 및 경질 캡슐제인 경우, 락토스, 수크로스, 전분 또는 그 유도체, 탈크, 칼슘 카보네이트, 젤라틴, 스테아르산 또는 그 염을 사용할 수 있다. 또한, 제형이 연질 캡슐제인 경우에는, 식물성 오일, 왁스, 지방, 반고체 및 액체의 폴리올이 사용 가능하다. 또한, 제형이 용액 또는 시럽 형태인 경우, 물, 폴리올, 글리세롤, 및 식물성 오일 등이 사용될 수 있다.The composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, when the formulation is a tablet, coated tablet, dragee and hard capsule, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof can be used. In addition, when the formulation is a soft capsule, polyols of vegetable oils, waxes, fats, semisolids and liquids can be used. In addition, when the formulation is in the form of a solution or syrup, water, polyols, glycerol, vegetable oils and the like can be used.
본 발명에 따른 조성물은 상기의 담체외에도 보존제, 안정화제, 습윤제, 유화제, 용해제, 감미제, 착색제, 삼투압 조절제, 산화방지제 등을 더 포함할 수 있다.The composition according to the present invention may further include a preservative, a stabilizer, a wetting agent, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic agent, an antioxidant, and the like in addition to the above carrier.
본 발명에 따른 조성물의 투여방법은 제형에 따라 용이하게 선택될 수 있으며, 경구 또는 비경구 투여될 수 있다. 투여량은 환자의 나이, 성별, 체중, 병증의 정도, 투여경로에 따라 달라질 수 있으나, 일반적으로 유효성분인 세포외다당체를 기준으로 5 내지 500 mg/kg체중의 양, 구체적으로는 100 내지 250 mg/kg체중의 양을 1일 1회 내지 3회로 나누어 투여할 수 있다. 그러나, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally. The dosage may vary depending on the patient's age, sex, weight, severity, and route of administration, but is generally 5 to 500 mg / kg body weight, specifically 100 to 250 based on the extracellular polysaccharide as an active ingredient. The amount of mg / kg body weight may be administered once to three times a day. However, the dosage does not limit the scope of the invention in any aspect.
또한, 본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물을 유효성분으로 포함하는, 피로회복 증진용 건강기능식품을 제공한다.In addition, the present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the same, the dry powder of the mycelium culture solution or the extract of the mycelium culture solution active ingredient Including, to provide a functional dietary supplement for fatigue recovery.
상기 세리포리아 락세라타에 의해 생산되는 세포외다당체, 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물 각각은 전술한 바와 같다.The extracellular polysaccharide produced by the Seriphoria laccerata, the mycelium culture solution of the Seriporia laccerata, the dry powder of the mycelium culture solution or the extract of the mycelium culture medium are as described above.
본 발명에 따른 건강기능식품은 분말, 과립, 정제, 캡슐 또는 음료의 형태일 수 있고, 캔디, 초콜릿, 음료, 껌, 차, 비타민복합체 또는 건강보조식품일 수 있다.The health functional food according to the present invention may be in the form of powder, granules, tablets, capsules or beverages, and may be candy, chocolate, beverages, gums, teas, vitamin complexes or dietary supplements.
이때, 상기 건강기능식품 중에 포함되는 본 발명에 따른 세포외다당체, 이를 포함하는 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물의 함량은, 통상적으로 전체 식품 중량의 0.01 내지 50 중량%, 구체적으로는 0.1 내지 20 중량%로 포함될 수 있다. 또한, 상기 건강기능식품이 음료일 경우, 음료 100 ㎖를 기준으로, 본 발명에 따른 세포외다당체, 이를 포함하는 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물을, 0.02 내지 10 g, 구체적으로는 0.3 내지 1 g의 함량으로 포함할 수 있다.In this case, the content of the extracellular polysaccharide according to the present invention contained in the health functional food, mycelium culture medium containing the same, the dry powder of the mycelium culture medium or the extract of the mycelium culture medium, usually 0.01 to 50% by weight of the total food weight Specifically, it may be included in 0.1 to 20% by weight. In addition, when the health functional food is a beverage, based on 100 ml of the beverage, extracellular polysaccharide according to the present invention, mycelium culture medium containing the same, dry powder of the mycelium culture medium or extract of the mycelium culture medium, 0.02 to 10 g For example, the content may be included in an amount of 0.3 to 1 g.
상기 건강기능식품은 본 발명의 세포외다당체, 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물과 함께 식품학적으로 허용가능한 식품 보조 첨가제를 더 포함할 수 있다.The health functional food further comprises a food supplement acceptable with the extracellular polysaccharide of the present invention, a mycelium culture medium of the seriporia laccerata containing the same, a dry powder of the mycelium culture medium or an extract of the mycelium culture medium. Can be.
본 발명은 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물을 피로회복이 필요한 대상에 투여하는 것을 포함하는, 피로회복 방법을 제공한다.The present invention is an extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata comprising the extracellular polysaccharide, the dry powder of the mycelium culture medium, or the extract of the mycelium culture solution It provides a method for fatigue recovery, comprising administering to a subject in need of fatigue recovery.
상기 대상은 포유류 동물, 보다 구체적으로 인간일 수 있다.The subject may be a mammalian animal, more specifically a human.
나아가, 본 발명은 피로회복을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물의 용도를 제공한다.Furthermore, the present invention is an extracellular polysaccharide produced by Ceriporia lacerata for use in the manufacture of a medicament for fatigue recovery, mycelium culture medium of the Ceriporia laccerata comprising the extracellular polysaccharide. It provides a dry powder of the mycelium broth, or the use of the extract of the mycelium broth.
상기 세리포리아 락세라타에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물은 전술한 바와 같다.The extracellular polysaccharide produced by the Seriphoria laccerata, the mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide, the dry powder of the mycelium culture solution, or the extract of the mycelium culture medium is as described above.
이하, 본 발명을 하기 실시예에 의해 보다 상세하게 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
[[ 실시예Example ]]
제조예Production Example 1.  One. 세리포리아Serifolia 락세라타의Lacserata 균사체 배양액, 이의 건조분말, 추출물 및  Mycelium broth, its dry powder, extract and 세포외다당체Extracellular polysaccharide (exopolysaccharide; 이하, "EPS"라 함)의 제조(exopolysaccharide; hereinafter referred to as "EPS")
1-1: 1-1: 세리포리아Serifolia 락세라타의Lacserata 균사체 배양액의 제조 Preparation of Mycelia Culture
경북 상주시에서 채취한 참나무 변제부 속에서 분리한 세리포리아 락세라타 균사체를 계대배양을 통해 육성한 모균을 -80℃에 냉동보관하였다. 상기 냉동 보관중인 균주를 PDA(Potato dextrose agar) 배지(87 플라스틱 배양구; Difco, Becton Dickinson and Company)에서 2 ~ 3회 계대 후 균주(이하 "PDA 배양균주"라 함)를 4 ℃ 냉장고에 보관하여 사용하였다. 그리고 삼각플라스크에 PDB(Potato dextrose broth) 배지(Difco, Becton Dickinson and Company) 600 ㎖를 조성한 후, 여기에 PDA 배양 균주 1 개를 넣고 25℃에서 8 일간 진탕배양하여, PDB 배양 균주를 수득하였다.The seedlings grown in subcultured oak reimbursement in Sangju, Gyeongbuk were grown by subculture and stored frozen at -80 ℃. The cryopreserved strain was passaged 2-3 times in PDA (Potato dextrose agar) medium (87 plastic cultures; Difco, Becton Dickinson and Company) and stored the strain (hereinafter referred to as “PDA culture strain”) in a 4 ° C. refrigerator. Was used. Then, after preparing 600 ml of PDB (Potato dextrose broth) medium (Difco, Becton Dickinson and Company) in an Erlenmeyer flask, one PDA culture strain was added thereto, followed by shaking culture at 25 ° C. for 8 days to obtain a PDB culture strain.
한편, 균주의 배양을 위해 설탕 1.5 중량%, 포도당 0.5 중량%, 감자전분 0.5 중량%, 수수분 0.25 중량%, 대맥분 0.25 중량%, 대두분 0.75 중량%, 황산마그네슘(MgSO4) 0.05 중량%, 1인산칼륨(KH2PO4) 0.05 중량%, 2인산칼륨(K2HPO4) 0.05 중량% 및 잔량의 물을 포함하는 액체 배양 배지를 800 ℓ 발효조에서 121 ℃에서, 공기를 1.5 kgf/㎠으로 주입하여 20 분간 멸균하였다. 이후, 23 ℃로 냉각한 상태에서 스타터로 상기 PDB 배양 균주 600 ㎖를 접종하고, 공기를 0.5 ~ 1.5 kgf/㎠으로 통기시키면서, 광원은 청색 LED, 조도는 0.5 LUX를 유지하며, 이산화탄소의 농도는 2,000 ppm으로 세리포리아 락세라타 균사체를 23℃의 항온에서 10일간 액체 배양함으로써 세리포리아 락세라타의 균사체 배양액을 제조하였다.On the other hand, 1.5% by weight of sugar, 0.5% by weight of glucose, 0.5% by weight of potato starch, 0.25% by weight of water, 0.25% by weight of soybean meal, 0.75% by weight of soy flour, 0.05% by weight of magnesium sulfate (MgSO 4 ) , Liquid culture medium containing 0.05% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05% by weight of potassium diphosphate (K 2 HPO 4 ) and the balance of water at 121 ° C. in an 800 L fermenter and air at 1.5 kgf / Injected in cm 2 sterilized for 20 minutes. Thereafter, 600 ml of the PDB culture strain was inoculated with a starter while cooled to 23 ° C., while the air was aerated at 0.5 to 1.5 kgf / cm 2, the light source maintained the blue LED, the illuminance was 0.5 LUX, and the concentration of carbon dioxide was The mycelium culture of Ceriporia laccerata was prepared by liquid culture of the Ceriporia laccerata mycelium at 2,000 ppm for 10 days at a constant temperature of 23 ° C.
1-2: 1-2: 세리포리아Serifolia 락세라타의Lacserata 균사체 배양액의 건조분말의 제조 Preparation of dry powder of mycelium culture
제조예 1-1에서 제조된 세리포리아 락세라타 균사체 배양액을 진공동결건조기를 이용하여 25 ℃에서 72 시간 동안 동결건조시켜 분말화함으로써 세리포리아 락세라타의 균사체 배양액의 건조분말을 제조하였다.The dry powder of the mycelium culture medium of Seriphoria laccerata was prepared by lyophilizing the culture medium of the culture medium of Liporice laccerata prepared in Preparation Example 1-1 by lyophilizing at 25 ° C. for 72 hours.
1-3: 1-3: 세리포리아Serifolia 락세라타의Lacserata 균사체 배양액의 추출물의 제조 Preparation of extract of mycelium culture
제조예 1-2에서 제조된 세리포리아 락세라타의 균사체 배양액의 건조분말 5 g에 증류수 100 ㎖를 첨가하여 잘 현탁한 후, 8,000 rpm으로 20 분 동안 원심분리하였다. 이의 상등액에 상등액 부피의 2 ~ 3배에 해당하는 에탄올을 첨가하고 4 ℃에서 12 시간 정치시켰다. 이후 정치물에서 상등액을 취해 세리포리아 락세라타의 균사체 배양액의 추출물을 제조하였다.100 ml of distilled water was added to 5 g of the dry powder of the mycelium culture medium of Ceriporia laccerata prepared in Preparation Example 1-2, and then suspended well, and centrifuged at 8,000 rpm for 20 minutes. Ethanol corresponding to 2-3 times the volume of the supernatant was added to the supernatant, and the mixture was allowed to stand at 4 ° C. for 12 hours. Then, the supernatant was taken from the stationary material to prepare an extract of the mycelium culture medium of Seriporia laccerata.
1-4 1-4 세리포리아Serifonia 락세라타의Lacserata 균사체 배양액으로부터 EPS의 제조 Preparation of EPS from Mycelial Culture
제조예 1-3에서 제조된 세리포리아 락세라타의 균사체 배양액의 추출물을 다시 8,000 rpm으로 20 분 동안 원심분리한 후, 침전물을 회수하여 조(crude) EPS를 얻었다. 조 EPS를 진공동결건조기를 이용하여 25℃에서 72시간 진공동결건조시켜 세리포리아 락세라타에 의해 생산되는 EPS를 획득하였다.The extract of the mycelium culture medium of Seriphoria laccerata prepared in Preparation Example 1-3 was further centrifuged at 8,000 rpm for 20 minutes, and the precipitate was recovered to obtain a crude EPS. The crude EPS was vacuum-dried at 25 ° C. for 72 hours using a vacuum freeze dryer to obtain EPS produced by Ceriporia laccerata.
실시예Example 1. EPS의 특성 평가 1. Characterization of EPS
1-1: 1-1: 겔투과Gel permeation 크로마토그래피(Gel Permeation Chromatography,  Chromatography (Gel Permeation Chromatography, GPCGPC )를 이용한 EPS의 분자량 측정Molecular weight of EPS using
제조예 1에서 제조한 EPS를 0.1 M Na2SO4/0.05 M NaN3[빙초산(glacial acetic acid)으로 pH를 4로 조정] 용액에 1%(w/v)가 되도록 녹인 다음, 4,000 rpm으로 0.5 시간 동안 원심분리 후, 상층액만을 0.45 ㎛ 시린지 필터(syringe filter)로 여과하여 GPC로 분석하였다.The EPS prepared in Preparation Example 1 was dissolved in 0.1 M Na 2 SO 4 /0.05 M NaN 3 [adjusting pH to 4 with glacial acetic acid] to 1% (w / v) in a solution, and then at 4,000 rpm. After centrifugation for 0.5 hour, only the supernatant was filtered with a 0.45 μm syringe filter and analyzed by GPC.
GPC 분석을 위한 조건은 검출기로 굴절지수를 이용하였으며, GPC 칼럼은 OHpak SB 805 HQ(Shodex, Japan)를 이용하여 이동상을 0.1 M Na2SO4/0.05 M NaN3[빙초산으로 pH를 4로 조정]을 사용하였으며, 이동상의 유속은 1.0 ㎖/분의 속도로 흘려주었다. 표준곡선은 각기 다른 분자량(130 kDa, 400 kDa, 770 kDa 또는 1200 kDa)을 가진 덱스트란(American Polymer Corporation, USA)을 이용하여 작성하였으며, 굴절지수(refractive index, RI) 측정기 Knauer K-2310(Germany)를 이용하여 EPS의 분자량을 측정하였다. 측정 조건을 정리하면 하기 표 1과 같다.For the GPC analysis, the refractive index was used as the detector, and the GPC column was adjusted to pH 4 with 0.1 M Na 2 SO 4 /0.05 M NaN 3 [glacial acetic acid using OHpak SB 805 HQ (Shodex, Japan). ], The flow rate of the mobile phase was flowed at a rate of 1.0 mL / min. Standard curves were prepared using Dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa, or 1200 kDa), and Knauer K-2310 (refractive index (RI) measuring instrument). Germany) to determine the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
분자량의 측정Measurement of molecular weight
GPC 시스템GPC system Knauer K-501 시스템Knauer K-501 System
칼럼column OHpak SB 805 HQ (Shodex, Japan)OHpak SB 805 HQ (Shodex, Japan)
이동상Mobile phase 0.1 M Na2SO4 / 0.05 M NaN3 / pH40.1 M Na 2 SO 4 / 0.05 M NaN 3 / pH 4
유속Flow rate 1.0 ㎖/분1.0 ml / min
측정기Measuring instrument RI(Knauer K-2310)RI (Knauer K-2310)
그 결과, 본 발명의 EPS의 분자량은 약 120 kDa으로 나타났다.As a result, the molecular weight of EPS of the present invention was found to be about 120 kDa.
1-2: EPS의 당 및 단백질 함량 측정1-2: Determination of sugar and protein content of EPS
제조예 1에서 제조한 EPS를 2차 정제하고 단백질 가수분해 효소를 처리하여 당 및 단백질 함량을 측정하였다.The EPS prepared in Preparation Example 1 was second-purified and treated with proteolytic enzymes to determine sugar and protein content.
구체적으로, 1차 정제된 EPS(제조예 1에서 제조한 EPS)를 증류수에 녹이고 8,000 rpm으로 20 분 동안 원심분리하여 상등액을 분리하였다. 분리된 상등액에 상등액 부피의 2 ~ 3배에 해당하는 에탄올을 첨가하고 4 ℃ 냉장고에 넣어 12 시간 정치시켰다. 이후 정치물에서 상등액만을 다시 8,000 rpm으로 20 분 동안 원심분리한 후, 침전물을 회수하여 2차 정제된 EPS를 획득하였다. 상기 2차 정제된 EPS를 증류수에 용해하고, 단백질 가수분해 효소인 알칼레이즈(alcalase)를 0.5%(w/v)의 농도로 50℃에서 30분간 처리하였다.Specifically, the super purified EPS (EPS prepared in Preparation Example 1) was dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant. Ethanol corresponding to 2-3 times the volume of the supernatant was added to the separated supernatant and placed in a 4 ° C. refrigerator for 12 hours. Thereafter, only the supernatant was again centrifuged at 8,000 rpm for 20 minutes, and the precipitate was recovered to obtain a second purified EPS. The second purified EPS was dissolved in distilled water, and the proteolytic enzyme alcalase was treated at 50 ° C. for 30 minutes at a concentration of 0.5% (w / v).
당 함량은 페놀-황산법(phenol-sulfuric acid method)에 의해 측정하였다. 구체적으로, 농도별로 희석한 시료 1 ㎖에 80%(w/v) 페놀을 25 ㎕ 첨가한 후 황산 2.5 ㎖를 첨가하고 실온으로 냉각하였다. 이를 465 nm에서 흡광도를 측정하여 당 함량을 계산하였다.Sugar content was measured by the phenol-sulfuric acid method. Specifically, 25 μl of 80% (w / v) phenol was added to 1 mL of the sample diluted by concentration, and then 2.5 mL of sulfuric acid was added and cooled to room temperature. The absorbance was measured at 465 nm to calculate the sugar content.
또한, 단백질 함량은 BCA 방법(Smith PK et al., Analytical Biochemistry, 150(1):76-85, 1985)으로 측정되었고, 표준품으로 소혈청알부민을 사용하였다.In addition, the protein content was measured by the BCA method (Smith PK et al., Analytical Biochemistry , 150 (1): 76-85, 1985), and bovine serum albumin was used as a standard.
상술한 바와 같이 측정한 당 및 단백질 함량은 하기 표 2에 나타냈으며, EPS의 당 함량은 45 ~ 51 중량%이고 단백질 함량은 33 ~ 34 중량%인 것으로 나타났다.The sugar and protein content measured as described above are shown in Table 2 below, wherein the EPS content was found to be 45-51 wt% and the protein content was 33-34 wt%.
수율(%)yield(%) 총 당 함량(%)Total sugar content (%) 총 단백질 함량(%)Total protein content (%)
EPSEPS 1.22±0.031.22 ± 0.03 45.32±1.4145.32 ± 1.41 34.17±0.7334.17 ± 0.73
2차 정제된 EPSSecondary Refined EPS 0.78±0.010.78 ± 0.01 50.49±0.5250.49 ± 0.52 33.50±2.7933.50 ± 2.79
효소 처리된 EPS* Enzyme-treated EPS * 0.24±0.060.24 ± 0.06 51.39±1.3251.39 ± 1.32 34.61±1.5134.61 ± 1.51
*효소 처리: 알칼레이즈 0.5%, 50℃, 30분. * Enzyme treatment: 0.5% Al Calle Izu, 50 ℃, 30 minutes.
각 수치는 평균±SE(n≥3)임.Each figure is mean ± SE (n≥3).
또한, EPS의 당 구성 분석 결과, EPS는 주로 만노오스, 갈락토오스 및 글루코오스를 함유하고 있는 것으로 나타났다.In addition, the results of the sugar composition analysis of EPS, EPS mainly contained mannose, galactose and glucose.
실시예Example 2. EPS의 피로회복 증진 효과 측정 2. Measurement of EPS's fatigue recovery enhancement effect
제조예 1의 EPS의 피로회복 증진 효과를 확인하기 위하여, EPS를 투여한 시험동물에 대해 강제수영 시험을 실시하고 수영시간의 증가 정도로 피로회복 증진 효과를 평가하였다.In order to confirm the fatigue recovery enhancement effect of EPS of Preparation Example 1, the test animals administered EPS were subjected to a forced swimming test, and the fatigue recovery enhancement effect was evaluated to increase the swimming time.
구체적으로, 8 주령의 ICR 마우스에 제조예 1의 EPS를 음용수에 분산시켜 준비하고 존대를 이용하여 1주간 실험동물에 투여하였다. 투여량은 1일 1회 100 ㎎/㎏체중, 250 ㎎/㎏체중 또는 500 ㎎/㎏체중으로 하였다. 비교를 위해, 양성대조군의 경우, EPS 대신 홍삼농축액(제조사: 정관장, 제품명: 홍삼정 플러스)을 500 ㎎/㎏체중을 투여하거나, 음성대조군의 경우, 음용수를 투여하였다. 강제수영장치는 도 1에 나타낸 마츠모토식 유영유수조를 사용하였고 유속은 30 L/분으로 조절하였다.Specifically, 8-week-old ICR mice were prepared by dispersing EPS of Preparation Example 1 in drinking water and administered to experimental animals for 1 week using zonation. The dose was 100 mg / kg body weight, 250 mg / kg body weight or 500 mg / kg body weight once daily. For comparison, in the positive control group, red ginseng concentrate (manufacturer: Jeong Kwan Jang, product name: red ginseng tablet plus) was administered 500 mg / kg body weight, and in the negative control group, drinking water was administered. The forced swimming device used the Matsumoto swimming pool shown in Fig. 1 and the flow rate was adjusted to 30 L / min.
시험당일(실험시작 후 3일과 7일 경과 후) 실험동물에게 EPS(실험군), 홍삼농축액(양성대조군) 또는 음용수(음성대조군)을 투여하고 60분 후 최장 수영시간을 측정하였다. 실험동물 체중의 약 5%에 달하는 추를 꼬리에 달아 부하를 주었고, 최장 수영시간은 실험동물의 머리가 물 아래로 5초 이상 잠긴 시점으로 정하였다. 실험 7일째에는 수영 종료 후 60분의 휴식시간을 두고 반복하여 최장 수영시간을 측정하였으며, 측정된 최장 수영시간은 도 2에 나타냈다. 또한, 실험 7일차 강제수영 이후 피로 유발물질인 혈청 내의 LDH 수준을 측정하여 도 3에 나타내었다.On the day of the test (after 3 and 7 days after the start of the experiment), the experimental animals were dosed with EPS (experimental group), red ginseng concentrate (positive control group) or drinking water (negative control group), and the longest swimming time was measured after 60 minutes. A weight of about 5% of the weight of the test animals was attached to the tail, and the longest swimming time was set to the point where the head of the test animal was submerged for 5 seconds or more under water. On the seventh day of the experiment, the longest swimming time was measured repeatedly with a rest time of 60 minutes after the end of swimming, and the measured longest swimming time is shown in FIG. 2. In addition, LDH levels in serum, which is a fatigue-inducing substance after the 7th day of forced swimming, are shown in FIG.
도 2에서 보는 바와 같이, 실험 3일차 강제수영 시, 음성대조군과 양성대조군과 비교하여, 본 발명의 EPS를 100 ㎎/㎏체중 또는 250 ㎎/㎏체중 투여한 실험군에서 유의적으로 수영시간이 증가하였다. 또한, 실험 7일차 강제수영 시, 본 발명의 EPS를 투여한 실험군에서 수영시간이 증가하였다.As shown in FIG. 2, the swimming time was significantly increased in the experimental group administered 100 mg / kg body weight or 250 mg / kg body weight of the EPS of the present invention when compared to the negative control group and the positive control group during the forced swimming on the third day of the experiment. It was. In addition, the swimming time was increased in the experimental group administered the EPS of the present invention during the forced swimming on the 7th day of the experiment.
도 3에서 보는 바와 같이, 음성대조군과 비교하여, 본 발명의 EPS를 투여한 실험군 모두에서 피로 유발물질인 혈청 내의 LDH가 감소하였다.As shown in FIG. 3, compared to the negative control group, LDH in serum, a fatigue-inducing substance, was reduced in all the experimental groups to which the EPS of the present invention was administered.

Claims (19)

  1. 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물을 유효성분으로 함유하는, 피로회복 증진용 조성물.Extracellular polysaccharide produced by Ceriporia lacerata ( Ceriporia lacerata ), mycelium culture medium of the seriporia laccerata containing the extracellular polysaccharide, dry powder of the mycelium culture solution or extract of the mycelium culture medium as an active ingredient A composition for promoting fatigue recovery containing.
  2. 제1항에 있어서,The method of claim 1,
    상기 세포외다당체가 40 ~ 60 중량%의 당 및 30 ~ 40 중량%의 단백질을 포함하고, 100 ~ 150 kDa의 분자량을 갖는, 피로회복 증진용 조성물.The extracellular polysaccharide comprises 40 to 60% by weight of sugar and 30 to 40% by weight of protein, having a molecular weight of 100 to 150 kDa, fatigue recovery composition.
  3. 제2항에 있어서,The method of claim 2,
    상기 세포외다당체가 43 ~ 47 중량%의 당 및 33 ~ 36 중량%의 단백질을 포함하고, 115 ~ 125 kDa의 분자량을 갖는, 피로회복 증진용 조성물.The extracellular polysaccharide comprises 43 to 47% by weight of sugar and 33 to 36% by weight of protein, and has a molecular weight of 115 to 125 kDa, fatigue recovery composition.
  4. 제2항에 있어서,The method of claim 2,
    상기 당이 만노오스, 갈락토오스 및 글루코오스를 함유하는, 피로회복 증진용 조성물.The sugar contains mannose, galactose and glucose, fatigue recovery composition.
  5. 제1항에 있어서,The method of claim 1,
    상기 세포외다당체가, The extracellular polysaccharide,
    (a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타의 균사체 배양액을 제조하는 단계; (a) liquid culture of the seriporia laccerata mycelium to prepare a mycelium culture medium of the seriporia laccerata;
    (b) 상기 세리포리아 락세라타의 균사체 배양액을 건조시켜 분말화하는 단계; 및 (b) drying the powdered mycelium culture medium of the seriporia laccerata; And
    (c) 세리포리아 락세라타의 균사체 배양액의 건조분말을 용매로 추출한 후 이를 여과하고 감압농축하는 단계를 포함하는 제조방법에 의하여 제조된, 피로회복 증진용 조성물.(c) extracting the dry powder of the mycelium culture medium of the seriporia laccerata with a solvent and then filtering and concentrating under reduced pressure, a composition for improving fatigue recovery.
  6. 제5항에 있어서,The method of claim 5,
    상기 액체 배양을 위한 배지가 설탕, 포도당, 전분, 수수분, 대맥분, 대두분, 황산마그네슘(MgSO4), 1인산칼륨(KH2PO4), 2인산칼륨(K2HPO4) 및 물을 포함하고, 수소이온농도가 pH 4.5 ~ 6.0인, 피로회복 증진용 조성물.The medium for culturing the liquid is sugar, glucose, starch, hydrated water, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium monophosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water To include, the hydrogen ion concentration is pH 4.5 ~ 6.0, fatigue recovery composition.
  7. 제5항에 있어서,The method of claim 5,
    상기 액체 배양이 청색 LED 광원 하에서 수행되고, 이산화탄소의 농도를 1,000 ~ 2,000 ppm으로 유지하여 수행되고, 피로회복 증진용 조성물.The liquid culture is carried out under a blue LED light source, is carried out by maintaining the concentration of carbon dioxide at 1,000 ~ 2,000 ppm, fatigue recovery composition.
  8. 제1항에 있어서,The method of claim 1,
    상기 세포외다당체가 조성물 총 중량 대비 0.1 내지 80 중량%의 함량으로 포함되는, 피로회복 증진용 조성물.The extracellular polysaccharide is included in an amount of 0.1 to 80% by weight relative to the total weight of the composition, fatigue recovery composition.
  9. 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 이를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말 또는 상기 균사체 배양액의 추출물을 유효성분으로 포함하는, 피로회복 증진용 건강기능식품. Fatigue comprising extracellular polysaccharide produced by Ceriporia lacerata , mycelium culture solution of Ceriporia laccerata , dried powder of the mycelium culture solution or extract of the mycelium culture solution as an active ingredient. Health functional foods to promote recovery.
  10. 제9항에 있어서,The method of claim 9,
    상기 세포외다당체가 40 ~ 60 중량%의 당 및 30 ~ 40 중량%의 단백질을 포함하고, 100 ~ 150 kDa의 분자량을 갖는, 피로회복 증진용 건강기능식품.The extracellular polysaccharide comprises 40 to 60% by weight of sugar and 30 to 40% by weight of protein, and has a molecular weight of 100 to 150 kDa, health functional food for fatigue recovery.
  11. 제10항에 있어서,The method of claim 10,
    상기 세포외다당체가 43 ~ 47 중량%의 당 및 33 ~ 36 중량%의 단백질을 포함하고, 115 ~ 125 kDa의 분자량을 갖는, 피로회복 증진용 건강기능식품.The extracellular polysaccharide comprises 43 to 47% by weight of sugar and 33 to 36% by weight of protein, and has a molecular weight of 115 to 125 kDa, health functional food for promoting fatigue recovery.
  12. 제10항에 있어서,The method of claim 10,
    상기 당이 만노오스, 갈락토오스 및 글루코오스를 함유하는, 피로회복 증진용 건강기능식품.The sugar containing mannose, galactose and glucose, health functional food for promoting fatigue recovery.
  13. 제9항에 있어서,The method of claim 9,
    상기 세포외다당체가, The extracellular polysaccharide,
    (a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타의 균사체 배양액을 제조하는 단계; (a) liquid culture of the seriporia laccerata mycelium to prepare a mycelium culture medium of the seriporia laccerata;
    (b) 상기 세리포리아 락세라타의 균사체 배양액을 건조시켜 분말화하는 단계; 및 (b) drying the powdered mycelium culture medium of the seriporia laccerata; And
    (c) 세리포리아 락세라타의 균사체 배양액의 건조분말을 용매로 추출한 후 이를 여과하고 감압농축하는 단계를 포함하는 제조방법에 의하여 제조된, 피로회복 증진용 건강기능식품.(c) extracting the dry powder of the mycelium culture medium of Seriphoria laccerata with a solvent and then filtering and concentrating under reduced pressure, a health functional food for improving fatigue recovery.
  14. 제13항에 있어서,The method of claim 13,
    상기 액체 배양을 위한 배지가 설탕, 포도당, 전분, 수수분, 대맥분, 대두분, 황산마그네슘(MgSO4), 1인산칼륨(KH2PO4), 2인산칼륨(K2HPO4) 및 물을 포함하고, 수소이온농도가 pH 4.5 ~ 6.0인, 피로회복 증진용 건강기능식품.The medium for culturing the liquid is sugar, glucose, starch, hydrated water, soybean meal, soybean meal, magnesium sulfate (MgSO 4 ), potassium monophosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water To include, the hydrogen ion concentration is pH 4.5 ~ 6.0, health functional food for fatigue recovery enhancement.
  15. 제13항에 있어서,The method of claim 13,
    상기 액체 배양이 청색 LED 광원 하에서 수행되고, 이산화탄소의 농도를 1,000 ~ 2,000 ppm으로 유지하여 수행되고, 피로회복 증진용 건강기능식품.The liquid culture is carried out under a blue LED light source, the carbon dioxide is maintained by maintaining the concentration of 1,000 to 2,000 ppm, the health functional food for promoting fatigue recovery.
  16. 제9항에 있어서,The method of claim 9,
    상기 건강기능식품이 분말, 과립, 정제, 캡슐 또는 음료의 형태인, 피로회복 증진용 건강기능식품.The health functional food is in the form of a powder, granules, tablets, capsules or beverages, fatigue functional health functional food.
  17. 제9항에 있어서,The method of claim 9,
    상기 건강기능식품이 캔디, 초콜릿, 음료, 껌, 차, 비타민복합체 또는 건강보조식품인, 피로회복 증진용 건강기능식품.The health functional food is candy, chocolate, beverages, gum, tea, vitamin complexes or health supplement foods, fatigue functional health functional foods.
  18. 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물을 피로회복이 필요한 대상에 투여하는 것을 포함하는, 피로회복 방법. Fatigue recovery of the extracellular polysaccharide produced by Ceriporia lacerata , the mycelium culture solution of the Ceriporia laccerata containing the extracellular polysaccharide, the dry powder of the mycelium culture solution, or the extract of the mycelium culture solution A fatigue recovery method comprising administering to a subject in need thereof.
  19. 피로회복을 위한 약제의 제조에 사용하기 위한, 세리포리아 락세라타(Ceriporia lacerata)에 의해 생산되는 세포외다당체, 상기 세포외다당체를 포함하는 세리포리아 락세라타의 균사체 배양액, 상기 균사체 배양액의 건조분말, 또는 상기 균사체 배양액의 추출물의 용도.Extracellular polysaccharide produced by Ceriporia lacerata , mycelium culture medium of Ceriporia laccerata comprising the extracellular polysaccharide, for use in the preparation of a medicament for fatigue recovery, Use of dry powder or extract of the mycelium culture.
PCT/KR2016/008461 2015-08-06 2016-08-01 Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate WO2017023070A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0111300 2015-08-06
KR1020150111300A KR101712590B1 (en) 2015-08-06 2015-08-06 Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient

Publications (1)

Publication Number Publication Date
WO2017023070A1 true WO2017023070A1 (en) 2017-02-09

Family

ID=57943290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/008461 WO2017023070A1 (en) 2015-08-06 2016-08-01 Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate

Country Status (2)

Country Link
KR (1) KR101712590B1 (en)
WO (1) WO2017023070A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101853428B1 (en) 2017-09-21 2018-04-30 김영호 Mutant of Ceriporia lacerata and preparing method thereof
KR102659899B1 (en) 2023-06-26 2024-04-23 주식회사 건배 Nutraceutical composition comprising milk thistle extract and rhodiola rosea extract, and method of making the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101866850B1 (en) 2017-03-29 2018-06-14 (주)퓨젠바이오 Anti-inflammatory composition comprising submerged culture of ceriporia lacerata mycellium as an active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (en) * 2010-11-11 2011-04-27 김병천 Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same
CN103173357A (en) * 2011-12-22 2013-06-26 高冬 Ceriporia lacerata and application thereof
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient
WO2014112666A1 (en) * 2013-01-18 2014-07-24 (주) 퓨젠바이오농업회사법인 Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101444614B1 (en) * 2013-08-01 2014-09-26 계명대학교 산학협력단 Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (en) * 2010-11-11 2011-04-27 김병천 Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same
CN103173357A (en) * 2011-12-22 2013-06-26 高冬 Ceriporia lacerata and application thereof
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient
WO2014112666A1 (en) * 2013-01-18 2014-07-24 (주) 퓨젠바이오농업회사법인 Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, JI - EUN ET AL.: "Hyperglycemic Effect of Submerged Culture Fxtract of Ceriporia Lacerata in Streptozotocin-induced Diabetic Rats", FOOD SCIENCE AND BIOTECHNOLOGY, vol. 21, no. 6, 2012, pages 1685 - 1693, XP055362772 *
KIM, JI - EUN: "Production of I'sxopolysaccharides by Submerged Culture of Ceriporia Lacerate and Their And-diabetic Effect", DOCTORATE THESIS, 2013, pages 1 - 127 *
SHIN, EUN JI ET AL.: "Hypoglycemic Effects of Submerged Culture of Ceriporia Lacerata Mycelium", KOREAN JOURNAL OF FOOD PRESERVATION, vol. 22, no. 1, 28 February 2015 (2015-02-28), pages 145 - 153, XP053034193 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101853428B1 (en) 2017-09-21 2018-04-30 김영호 Mutant of Ceriporia lacerata and preparing method thereof
KR102659899B1 (en) 2023-06-26 2024-04-23 주식회사 건배 Nutraceutical composition comprising milk thistle extract and rhodiola rosea extract, and method of making the same

Also Published As

Publication number Publication date
KR101712590B1 (en) 2017-03-07
KR20170017425A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
WO2017023070A1 (en) Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate
WO2018128280A1 (en) Biological method for preparing heme iron not derived from porcine blood
WO2010137846A2 (en) Composition for increasing the bioavailability of saponin
WO2017061769A1 (en) Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient
WO2019190157A2 (en) Adenosine-high production paecilomyces hepiali cs4 strain isolated from cordyceps sinensis
WO2016072697A1 (en) Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata
WO2020209690A1 (en) Pharmaceutical composition containing wild-walnut extract, fraction thereof, or physiologically active substance derived therefrom as active ingredient, and having effects of inhibiting production of advanced glycation end products and decomposing advanced glycation end products
WO2017061819A1 (en) Composition for improving blood circulation containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient
WO2016072710A1 (en) Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata
WO2020159063A1 (en) Complex mushroom mycelium composition having liver function-improving activity and preparation method therefor
EP0132981B1 (en) Hypotriglyceridemically active polysaccharides
KR101620815B1 (en) Composition for the prevention and treatment of inflammatory diseases comprising the penicillinolide A isolated from marine fungi
WO2017061787A1 (en) Composition for relieving hangovers containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient
WO2020004858A1 (en) Diabetes-alleviating or antioxidant composition comprising yeast extract and method for preparing yeast extract
WO2017131305A1 (en) Method for preparing anthocyanin oligomers by using coenzyme derived from aspergillus sp. strain
WO2017090970A1 (en) Composition for protecting skin from ultraviolet rays, which contains extracellular polysaccharide produced by means of ceriporia lacerata as active ingredient
WO2016072713A1 (en) Sexual function improving composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata
WO2017142306A1 (en) Pharmaceutical composition for preventing or treating degenerative brain diseases, containing extracellular polysaccharide produced by ceriporia lacerata as active ingredient
WO2019212202A1 (en) Composition for liver protection comprising turmeric extract and rice germ soybean fermented extract
KR101737626B1 (en) Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR100278361B1 (en) Pharmaceutical composition for preventing and treating osteoporosis
WO2023043218A1 (en) Composition comprising extract from cell mass of bacillus subtilis natto for improving memory
KR100487703B1 (en) Physiologically active substances tkr1785's, process for the preparation thereof, and microbe
EP4356757A1 (en) Microbial method for reproducing the human urolithin metabotypes in vitro and in vivo
WO2022173078A1 (en) Composition comprising composite mushroom mycelia for improving cognitive function and memory

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16833306

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.06.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16833306

Country of ref document: EP

Kind code of ref document: A1